SCYNEXIS (SCYX)
(Delayed Data from NSDQ)
$1.47 USD
-0.02 (-1.01%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $1.46 -0.01 (-0.34%) 7:50 PM ET
4-Sell of 5 4
D Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
SCYNEXIS, Inc. [SCYX]
Reports for Purchase
Showing records 1 - 20 ( 66 total )
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Cutting Bait on Brexafemme Launch, Focus on Development to Treat Hospital Fungal Infections; Rating Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
2Q22: Looking for Brexafemme Re-Acceleration Coming Out of Summer Doldrums, and rVVC Approval November 30; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
1Q22: Brexafemme Accleration Slow Coming; Lower Revs Plus Dilution Lower Our Target to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
4Q21: Brexafemme Rx Acceleration Through 2022; rVVC Indication Approval by Year-End; Reiterate Buy, Lower PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Brexafemme Positive CANDLE Result Supports rVVC Label Expansion by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
3Q21: Brexafemme Launched; Look to 2022 Sales Acceleration
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
2Q21: Brexafemme Rx Already Being Written As Boots Just Hit Ground; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Preparing for August Brexafemme VVC Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Brexafemme Gets 1st-Pass VVC Approval; 2H Launch Into Eager, Underserved Market; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
1Q21: Brexafemme VVC June 1 PDUFA Date Imminent; Expect Approval 4Q First Sales; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Financing Provides Runway Into Launch; Expect June Ibrex VVC Approval; Reiterate Buy, But Lower PT to $20 on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Ibrex VVC Priority Review Confirmed with NDA Acceptance; June 1, 2021 PDUFA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
3Q20: Ibrex VVC NDA Filed; See Relatively Low-Risk Approval Mid-21 Followed by CANDLE rVVC Phase 3 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Ibrex VVC NDA Filed; Expect Priority Review and Mid-21 Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Taking a Fresh Look at VVC; Now See Majority of Opportunity as "On-Label" After Expected 2021 Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
1Q20; Ibrex aVVC NDA Filing on Track for 2H; De-Risking Post Phase 3 Success Not Fairly Reflected; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
Ibrex Hits Stat Sig on All Endpoints in VANISH-306; That?s Twofor-Two in aVVC; We See Mid-2021 Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: SCYNEXIS, Inc.
Industry: Medical - Drugs
4Q19 Results; Imminent Ibrex aVVC Phase 3 Data in April; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O